Antimicrobial resistance presents an escalating global health challenge, characterised by a dearth of new antibiotics under development. Researchers at Sultan Qaboos University have identified three novel antimicrobial peptides (AMPs) from dromedary camels that effectively target multidrug-resistant bacteria. These AMPs offer potential alternatives to conventional drugs, marking a significant development in the fight against antibiotic resistance.
The study, published in Frontiers in Immunology (Volume 17, 21 January 2026), employed a combination of bioinformatics predictions and experimental validations. Techniques used included colony-forming assays, membrane permeability tests, and electron microscopy on strains such as MRSA and multidrug-resistant E. coli. Peptides CdPG-3 and CdCATH exhibited potent antibacterial activity against both Gram-positive and Gram-negative bacteria, inducing membrane damage and leakage while showing low toxicity to camel and human red blood cells at lower doses.
Camels possess a robust innate immunity, which includes these cathelicidin-like AMPs, potentially explaining their resistance to infections common in other ruminants. “This lays the foundation for exploring camel AMPs as therapeutics against resistant pathogens,” the study authors assert. Unlike traditional antibiotics, which are susceptible to resistance through target mutations, AMPs disrupt bacterial membranes broadly, thereby reducing adaptation risks. The peptides demonstrated low hemolytic activity in relevant species, supporting their safety for further development.
Future research will focus on optimising these AMPs for clinical use, leveraging Oman’s camel resources. This advancement could be crucial in developing new therapeutic strategies against resistant pathogens, addressing a critical need in global health.
